EFFICACY OF INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C - COMPARISON BETWEEN NONDRINKERS AND DRINKERS
EFFICACY OF INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C - COMPARISON BETWEEN NONDRINKERS AND DRINKERS
复制标题
DOI：
10.3109/00365529409094883
复制
发表时间：
1994-11-01
影响因子：
1.9
通讯作者：
ABE, H
中科院分区：
文献类型：
--
作者：
OKAZAKI, T;YOSHIHARA, H;ABE, H
背景：酒精被认为是调节慢性病毒性肝炎发展和预后的重要因素，但对酒精摄入与慢性丙型肝炎的相互作用知之甚少。本研究的目的是探讨饮酒是否影响干扰素治疗慢性丙型肝炎的疗效。方法：39例慢性丙型肝炎患者根据干扰素治疗前的饮酒量分为三组：不饮酒组(n=15)；III组(N 10)，每天摄入酒精70g以上，持续至少10年。干扰素(总剂量330+/-206MU)每日给药2周，然后间歇给药。饮酒者在干扰素治疗前、期间和之后至少戒酒1个月。持续应答者为治疗后持续6个月以上丙氨酸氨基转移酶(ALAT)正常的患者。治疗前后分别检测肝组织学(HAI评分)和血清丙型肝炎病毒(HCVRNA)。结果：干扰素治疗前ALAT水平、年龄、干扰素总剂量、肝组织学三组间差异均无统计学意义。持续应答率I、II、III组分别为53.3%、42.9%、0%，III组显著低于I组(P<；0.01)和II组(P<；0.01)。治疗后血清丙型肝炎病毒RNA转阴率分别为58.3%、20.0%和12.5%，丙型肝炎病毒转阴率明显低于丙型肝炎病毒转阴率(p<；0.05)。结论：干扰素治疗慢性丙型肝炎对酗酒者的疗效不如不饮酒者。
Background: Alcohol has been reported to be an important factor that modulates the development and prognosis of chronic Viral hepatitis; however, little is known about interaction of alcohol intake and chronic hepatitis C. The aim of this study was to examine whether alcohol drinking affects the effectiveness of interferon (IFN) therapy for chronic hepatitis C. Methods: Thirty-nine patients with chronic hepatitis C were divided into three groups on the basis of the amount of alcohol intake before IFN therapy: group I (n = 15), non-drinkers; group II (n = 14), less than 70 g/day; and group III (n 10), more than 70 g/day of ethanol intake for at least 10 years. The IFN (total dose, 330 +/- 206 MU) was administered daily for 2 weeks and then intermittently. Drinkers stayed abstinent for at least 1 month before, during, and after IFN therapy. The sustained responder was defined as the patient who showed normal alanine aminotransferase (ALAT) levels continuously for more than 6 months after the therapy. The liver histology (HAI score) and serum hepatitis C virus (HCV) RNA were also examined before and after the therapy. Results: There was no significant difference among the three groups in the level of ALAT before IFN therapy, age, total dose of IFN, and liver histology. The rates of sustained responders in groups I, II. and III were 53.3%, 42.9%, and 0%, respectively, resulting in a significantly lower rate in group III than in groups I (p < 0.01) and II (p < 0.01). The serum HCV-RNA turned negative after the therapy in 58.3%, 20.0%, and 12.5% of groups I, II, and III, respectively, leading to a significantly lower rate of disappearance of HCV-RNA in group III than in group I (p < 0.05). Conclusion: The IFN therapy for chronic hepatitis C was less effective in heavy drinkers than in nondrinkers.